Savara Inc Cash Flow Conversion Efficiency
Savara Inc cash flow conversion efficiency. Based on the latest financial reports, Savara Inc (SVRA) has a cash flow conversion efficiency ratio of -0.207x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.75 Million) by net assets ($143.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Savara Inc (2000–2025)
Cash flow conversion efficiency of Savara Inc from 2000 to 2025. This chart illustrates how Savara Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Savara Inc (SVRA) stock price for real-time trading data and today's change.
Savara Inc Cash Flow Conversion Ratio Explained
Savara Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Savara Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Savara Inc ranked by their cash flow conversion efficiency. Also see market cap of Savara Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
4DMEDICAL Ltd
AU:4DX
|
0.446x |
|
Ategrity Specialty Insurance Company Holdings
NYSE:ASIC
|
0.066x |
|
Wuxi Chipown Micro-electronics Ltd
SHG:688508
|
-0.010x |
|
Heritage Insurance Hldgs Inc
NYSE:HRTG
|
0.250x |
|
Tianjin You Fa Steel Pipe Group Stock Co Ltd
SHG:601686
|
-0.063x |
|
Gracell Biotechnologies Inc.
NASDAQ:GRCL
|
-0.039x |
|
Max Zipper Co Ltd
TWO:8932
|
0.110x |
|
Starlake Bioscience Co Inc Zhaoqing Guangdong
SHG:600866
|
0.149x |
Annual Cash Flow Conversion Efficiency for Savara Inc (2000–2025)
The table below shows the annual cash flow conversion efficiency of Savara Inc from 2000 to 2025. Review Savara Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $203.13 Million | $-101.04 Million | -0.497x | +4.28% |
| 2024-12-31 | $171.45 Million | $-89.09 Million | -0.520x | -42.85% |
| 2023-12-31 | $140.37 Million | $-51.06 Million | -0.364x | -13.46% |
| 2022-12-31 | $107.78 Million | $-34.55 Million | -0.321x | -15.58% |
| 2021-12-31 | $144.50 Million | $-40.08 Million | -0.277x | +55.17% |
| 2020-12-31 | $64.38 Million | $-39.84 Million | -0.619x | -39.45% |
| 2019-12-31 | $101.70 Million | $-45.12 Million | -0.444x | -- |
| 2018-12-31 | $0.00 | $-39.27 Million | x | -- |
| 2017-12-31 | $119.31 Million | $-28.23 Million | -0.237x | -201.43% |
| 2016-12-31 | $-35.88 Million | $-8.37 Million | 0.233x | +116.92% |
| 2015-12-31 | $23.89 Million | $-32.95 Million | -1.379x | -228.28% |
| 2014-12-31 | $58.66 Million | $-24.64 Million | -0.420x | -12.91% |
| 2013-12-31 | $47.81 Million | $-17.79 Million | -0.372x | -11.72% |
| 2012-12-31 | $41.79 Million | $-13.92 Million | -0.333x | -40.42% |
| 2011-12-31 | $56.78 Million | $-13.47 Million | -0.237x | +24.12% |
| 2010-12-31 | $26.69 Million | $-8.34 Million | -0.313x | +83.47% |
| 2009-12-31 | $6.67 Million | $-12.62 Million | -1.891x | +52.35% |
| 2008-12-31 | $6.00 Million | $-23.79 Million | -3.968x | -526.87% |
| 2007-12-31 | $31.03 Million | $-19.64 Million | -0.633x | +19.92% |
| 2006-12-31 | $19.96 Million | $-15.77 Million | -0.790x | -153.12% |
| 2005-12-31 | $-7.83 Million | $-11.65 Million | 1.488x | +456.18% |
| 2004-12-31 | $12.39 Million | $-5.18 Million | -0.418x | +23.41% |
| 2003-12-31 | $4.12 Million | $-2.25 Million | -0.545x | -142.20% |
| 2002-12-31 | $-852.73K | $-1.10 Million | 1.292x | -51.78% |
| 2001-12-31 | $-638.49K | $-1.71 Million | 2.680x | +1922.59% |
| 2000-12-31 | $14.61 Million | $-2.15 Million | -0.147x | -- |
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, P… Read more